tocilizumab - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.73 [0.54, 0.98]< 10%3 studies (3/-)98.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.81 [0.44, 1.48]< 140%2 studies (2/-)75.4 %some concernnot evaluable moderateimportant-
clinical improvement 1.64 [1.25, 2.15]> 10%1 study (1/-)100.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.56 [0.24, 1.31]< 10%1 study (1/-)90.7 %some concernnot evaluable moderateimportant-
ventilation 1.36 [0.39, 4.69]< 10%1 study (1/-)31.6 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.